Is NEO a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Mix shift into NGS carries the revenue line, with revenue (ttm) at ~$766M (four quarters ended June 30, 2026). The bear case rests on gAAP losses persist despite the improving adjusted figures, with a trailing twelve-month net loss near $53 million and no positive price-to-earnings ratio to anchor valuation. Analysts covering it are spread from $16.00 to $35.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. GAAP losses persist despite the improving adjusted figures, with a trailing twelve-month net loss near $53 million and no positive price-to-earnings ratio to anchor valuation. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $16.00, -1.0% from the $16.16 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Mix shift into NGS carries the revenue line. Next-generation sequencing revenue grew roughly 26% year over year in the second quarter of 2026 while total clinical volume rose about 2%. The most optimistic analyst target on NEO is $35.00, +116.6% from the $16.16 price. That figure is only reachable if this thesis works close to its best case.

GAAP losses persist despite the improving adjusted figures, with a trailing twelve-month net loss near $53 million and no positive price-to-earnings ratio to anchor valuation. Reimbursement concentration is the structural exposure: Medicare through MolDx and commercial payors set the prices behind that rising revenue-per-test figure, and evolving regulation of laboratory developed tests could raise the compliance cost of the same menu. Growth is currently priced rather than volume driven, since clinical test count rose only about 2% year over year, so any payor pushback on pricing would hit revenue quickly. On litigation, a purported securities class action captioned Goldenberg v. NeoGenomics (S.D.N.Y., No. 22-cv-10314, filed December 16, 2022, covering purchases between February 27, 2020 and April 26, 2022) was dismissed with prejudice on March 13, 2026, and the plaintiff appealed to the Second Circuit on April 10, 2026; related shareholder derivative actions in Nevada, Florida and New York remain stayed pending that appeal, and the company states the outcome is not currently estimable. Finally, goodwill and intangibles of roughly $795 million sit on a $1.35 billion balance sheet alongside about $385 million of convertible principal, and the 2025 InVisionFirst-Lung write-down showed that impairment of acquired assets is a live possibility. The most pessimistic published target is $16.00, -1.0% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

NeoGenomics runs a specialised oncology testing laboratory network serving pathologists, oncologists and pharmaceutical partners.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Mix shift into NGS carries the revenue line) stalling in the reported numbers rather than in the narrative, the risk above (gAAP losses persist despite the improving adjusted figures, with a trailing twelve-month net loss near $53 million and no positive price-to-earnings ratio to anchor valuation) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

It runs cancer diagnostic tests. Oncologists and pathologists send tumor tissue or blood samples to its CLIA-certified, CAP-accredited labs, which perform FISH, IHC, PCR and next-generation sequencing to identify the genetic characteristics of a cancer. Pharmaceutical companies also pay it for clinical trial testing and oncology data services.

Not on a GAAP basis. The trailing twelve-month net loss is roughly $53 million, and full-year 2026 guidance calls for a net loss of about $34 million to $42 million. Second-quarter 2026 did show GAAP net income of about $2 million, though that included an $11 million gain on debt extinguishment rather than operating improvement alone.

Trailing twelve-month revenue is about $766 million and the market capitalization is roughly $2.1 billion, or about $16 per share across roughly 128.5 million shares as of August 2026. That works out to roughly 2.7 times trailing sales, with an enterprise value near $2.3 billion after netting about $146 million of cash against roughly $385 million of convertible principal.